Deben Dey

Deben Dey has worked in the field of biochemistry and pharmacology since 1992. Deben began their career as a Post-doctoral Fellow at the University of California, Davis, where they developed skills in ribosomal protein biochemistry. Deben then moved on to Calyx Therapeutics Inc. as a Senior Scientist and Founder Scientist, where they identified the first non-peptide insulin receptor agonist and a novel PPAR-g agonist with IK kinase inhibition for metabolic syndrome X. Deben also provided leadership in launching four new lead molecules to treat diabetes and arthritis. In 2002, they joined Orchid/Bexel Pharmaceuticals Inc. as Senior Research Director. There, they developed the first non-PPAR-gamma thiazolidinedione for type-II diabetes therapeutics, which reached phase Ia and Ib clinical trials. Deben also developed an orexin receptor agonist for obesity therapeutics, a TNF-a inhibitor and an IL-12 inhibitor for inflammatory bowel disease, and a novel anti-cancer drug for prostate cancer therapeutics. In 2008, they became the Head of Target Biology at Prosetta Biosciences Inc. and then in 2020, they were appointed Director of Biochemistry and Pharmacology at Epirium.

Deben Dey attended Banaras Hindu University from 1987 to 1992, where they earned a Doctor of Philosophy in Biochemistry and Molecular Biology.